Suppr超能文献

生物标本需求分析及国家肌萎缩侧索硬化症生物样本库样本利用

Analysis of Biospecimen Demand and Utilization of Samples from the National Amyotrophic Lateral Sclerosis Biorepository.

机构信息

Independent Consultant, Colorado Springs, Colorado, USA.

McKing Consulting Corporation, Atlanta, Georgia, USA.

出版信息

Biopreserv Biobank. 2021 Oct;19(5):432-437. doi: 10.1089/bio.2021.0039. Epub 2021 Jul 14.

Abstract

Amyotrophic lateral sclerosis (ALS) is a rare neurological condition affecting upper and lower motor neurons. The National ALS Biorepository (referred to as the Biorepository) was initiated in 2015, with biospecimen collection beginning in 2017, as a repository for biospecimens for future ALS research. To help ensure the usefulness of the Biorepository, a biospecimen demand analysis is conducted on an annual basis, as well as an analysis of the utilization of the Biorepository. To determine the types of biospecimens to be collected for the Biorepository, an in-depth initial examination occurred followed by ongoing biospecimen demand and utilization analyses. The initial examination included input from an expert panel, discussions with ALS research experts, review of other ALS biorepositories, assessment of biospecimen demand, and analysis of the biospecimen types historically used in ALS research. Of all biospecimen types reported in the literature, the most frequently used were DNA, postmortem spinal cord, blood, and cerebrospinal fluid; while the frequently reported types of biospecimens used in ALS-related grants were induced pluripotent stem cells, brain, blood, and spinal cord. Continuous analysis of potential sample demand and tissues collected, based on an analysis of the literature and funded grants, and actual sample requests can assist the Biorepository in ensuring that the appropriate samples are available for researchers when they are needed.

摘要

肌萎缩侧索硬化症(ALS)是一种罕见的影响上下运动神经元的神经疾病。国家肌萎缩侧索硬化症生物样本库(简称生物样本库)于 2015 年启动,2017 年开始收集生物样本,作为未来肌萎缩侧索硬化症研究的生物样本库。为了帮助确保生物样本库的有用性,每年进行生物样本需求分析和生物样本库利用分析。为了确定生物样本库要收集的生物样本类型,进行了深入的初步检查,然后进行了持续的生物样本需求和利用分析。初步检查包括专家小组的意见、与肌萎缩侧索硬化症研究专家的讨论、对其他肌萎缩侧索硬化症生物样本库的审查、对生物样本需求的评估,以及对肌萎缩侧索硬化症研究中历史上使用的生物样本类型的分析。在文献中报告的所有生物样本类型中,使用最频繁的是 DNA、尸检脊髓、血液和脑脊液;而在与肌萎缩侧索硬化症相关的资助中报告的经常使用的生物样本类型是诱导多能干细胞、大脑、血液和脊髓。基于文献分析和资助拨款以及实际样本请求对潜在样本需求和收集的组织进行持续分析,可以帮助生物样本库确保在研究人员需要时为他们提供适当的样本。

相似文献

1
Analysis of Biospecimen Demand and Utilization of Samples from the National Amyotrophic Lateral Sclerosis Biorepository.
Biopreserv Biobank. 2021 Oct;19(5):432-437. doi: 10.1089/bio.2021.0039. Epub 2021 Jul 14.
2
Biological, Medical, and Other Tissue Variables Affecting Biospecimen Utilization.
Biopreserv Biobank. 2019 Jun;17(3):258-263. doi: 10.1089/bio.2018.0094.
4
Ensuring Effective Utilization of Biospecimens: Design, Marketing, and Other Important Approaches.
Biopreserv Biobank. 2019 Jun;17(3):248-257. doi: 10.1089/bio.2019.0007.
5
The Utilization of Biospecimens: Impact of the Choice of Biobanking Model.
Biopreserv Biobank. 2019 Jun;17(3):230-242. doi: 10.1089/bio.2019.0008.
6
A cervical cancer biorepository for pharmacogenomics research in Zimbabwe.
BMC Cancer. 2022 Dec 16;22(1):1320. doi: 10.1186/s12885-022-10413-w.

引用本文的文献

1
Impact of the National Amyotrophic Lateral Sclerosis Registry: Analysis of Registry-funded Research.
Ann Clin Transl Neurol. 2022 Nov;9(11):1692-1701. doi: 10.1002/acn3.51660. Epub 2022 Oct 19.

本文引用的文献

1
Advancing Professionalization of Biobank Business Operations: Performance and Utilization.
Biopreserv Biobank. 2019 Jun;17(3):213-218. doi: 10.1089/bio.2019.0005.
2
Ensuring Effective Utilization of Biospecimens: Design, Marketing, and Other Important Approaches.
Biopreserv Biobank. 2019 Jun;17(3):248-257. doi: 10.1089/bio.2019.0007.
3
Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189.
4
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014.
MMWR Morb Mortal Wkly Rep. 2018 Feb 23;67(7):216-218. doi: 10.15585/mmwr.mm6707a3.
5
Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States.
Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16(1-2):65-71. doi: 10.3109/21678421.2014.971813. Epub 2014 Dec 8.
6
Neglected ethical issues in biobank management: Results from a U.S. study.
Life Sci Soc Policy. 2013 Dec 1;9(1):1. doi: 10.1186/2195-7819-9-1.
7
Underutilization of specimens in biobanks: an ethical as well as a practical concern?
Genet Med. 2014 Oct;16(10):738-40. doi: 10.1038/gim.2014.38. Epub 2014 Apr 24.
8
Characterizing biobank organizations in the U.S.: results from a national survey.
Genome Med. 2013 Jan 25;5(1):3. doi: 10.1186/gm407. eCollection 2013.
9
Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis.
J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):623-7. doi: 10.1136/jnnp.2010.224501. Epub 2010 Nov 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验